- Home
- LEGN vs CORT Comparison
LEGN vs CORT Comparison
Compare LEGN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGN
- CORT
- Stock Information
- Founded
- LEGN 2014
- CORT 1998
- Country
- LEGN United States
- CORT United States
- Employees
- LEGN N/A
- CORT N/A
- Industry
- LEGN Biotechnology: Pharmaceutical Preparations
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- LEGN Health Care
- CORT Health Care
- Exchange
- LEGN Nasdaq
- CORT Nasdaq
- Market Cap
- LEGN 7.0B
- CORT 7.1B
- IPO Year
- LEGN 2020
- CORT N/A
- Fundamental
- Price
- LEGN $27.80
- CORT $70.84
- Analyst Decision
- LEGN Strong Buy
- CORT Strong Buy
- Analyst Count
- LEGN 13
- CORT 4
- Target Price
- LEGN $75.67
- CORT $142.00
- AVG Volume (30 Days)
- LEGN 1.6M
- CORT 1.3M
- Earning Date
- LEGN 05-13-2025
- CORT 05-05-2025
- Dividend Yield
- LEGN N/A
- CORT N/A
- EPS Growth
- LEGN N/A
- CORT 8.36
- EPS
- LEGN N/A
- CORT 1.14
- Revenue
- LEGN $728,303,000.00
- CORT $685,446,000.00
- Revenue This Year
- LEGN $65.96
- CORT $35.85
- Revenue Next Year
- LEGN $52.55
- CORT $35.22
- P/E Ratio
- LEGN N/A
- CORT $61.79
- Revenue Growth
- LEGN 112.46
- CORT 30.93
- 52 Week Low
- LEGN $29.27
- CORT $25.35
- 52 Week High
- LEGN $60.87
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- LEGN 29.31
- CORT 51.25
- Support Level
- LEGN $30.25
- CORT $69.33
- Resistance Level
- LEGN $33.30
- CORT $73.36
- Average True Range (ATR)
- LEGN 1.72
- CORT 3.36
- MACD
- LEGN -0.41
- CORT -0.23
- Stochastic Oscillator
- LEGN 3.14
- CORT 45.66
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.